WO2021087851A1 - 一种重组病毒载体、包含其的免疫组合物以及用途 - Google Patents
一种重组病毒载体、包含其的免疫组合物以及用途 Download PDFInfo
- Publication number
- WO2021087851A1 WO2021087851A1 PCT/CN2019/116197 CN2019116197W WO2021087851A1 WO 2021087851 A1 WO2021087851 A1 WO 2021087851A1 CN 2019116197 W CN2019116197 W CN 2019116197W WO 2021087851 A1 WO2021087851 A1 WO 2021087851A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tumor
- antigen
- viral vector
- seq
- recombinant viral
- Prior art date
Links
- 239000013603 viral vector Substances 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims abstract description 15
- 230000002163 immunogen Effects 0.000 title abstract description 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 141
- 108091007433 antigens Proteins 0.000 claims abstract description 108
- 102000036639 antigens Human genes 0.000 claims abstract description 108
- 239000000427 antigen Substances 0.000 claims abstract description 107
- 229960005486 vaccine Drugs 0.000 claims abstract description 19
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims abstract description 18
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims abstract description 18
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims abstract description 7
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims abstract description 7
- 238000012737 microarray-based gene expression Methods 0.000 claims abstract description 6
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims abstract description 6
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 3
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 3
- 239000002157 polynucleotide Substances 0.000 claims abstract description 3
- 241000700618 Vaccinia virus Species 0.000 claims description 37
- 239000013598 vector Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 19
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 claims description 17
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 15
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 241000700605 Viruses Species 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 8
- 102000009016 Cholera Toxin Human genes 0.000 claims description 6
- 108010049048 Cholera Toxin Proteins 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000003362 replicative effect Effects 0.000 claims description 4
- 208000007089 vaccinia Diseases 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 241000700649 Vaccinia virus Tian Tan Species 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 230000004083 survival effect Effects 0.000 abstract description 27
- 210000004881 tumor cell Anatomy 0.000 abstract description 25
- 230000004614 tumor growth Effects 0.000 abstract description 19
- 230000037455 tumor specific immune response Effects 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 57
- 210000004027 cell Anatomy 0.000 description 31
- 241000699666 Mus <mouse, genus> Species 0.000 description 24
- 238000011081 inoculation Methods 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 19
- 238000002255 vaccination Methods 0.000 description 14
- 229940126580 vector vaccine Drugs 0.000 description 13
- 239000002609 medium Substances 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 238000012423 maintenance Methods 0.000 description 9
- 229940023143 protein vaccine Drugs 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 239000013605 shuttle vector Substances 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000010171 animal model Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 101100235725 Homo sapiens LMNB1 gene Proteins 0.000 description 4
- 102100026517 Lamin-B1 Human genes 0.000 description 4
- 238000001976 enzyme digestion Methods 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 229940023041 peptide vaccine Drugs 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000012096 transfection reagent Substances 0.000 description 4
- 210000003501 vero cell Anatomy 0.000 description 4
- 230000003321 amplification Effects 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 229940030156 cell vaccine Drugs 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 210000003771 C cell Anatomy 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 108090000143 Mouse Proteins Proteins 0.000 description 2
- 102000007298 Mucin-1 Human genes 0.000 description 2
- 108010008707 Mucin-1 Proteins 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 229940029030 dendritic cell vaccine Drugs 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 238000011176 pooling Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000016914 ras Proteins Human genes 0.000 description 2
- 108010014186 ras Proteins Proteins 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 229940030325 tumor cell vaccine Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 229940022005 RNA vaccine Drugs 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 108700021021 mRNA Vaccine Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940038237 tumor antigen vaccine Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
Definitions
- the invention belongs to the field of molecular biology and immunology. Specifically, the present invention relates to a recombinant viral vector, an immune composition containing the same, and use thereof. In particular, the present invention relates to a tumor therapeutic vaccine.
- tumor immunotherapy has made considerable progress, and has gradually become an important development direction of current tumor treatment.
- PD-1/PD-L1 immunotherapy the development of tumor immunotherapy has become an emerging hot spot in current tumor treatment.
- Tumor vaccines can kill and control the growth of tumor cells by stimulating a specific immune response against tumors in the body and activating huge immune cells, thereby achieving the effect of reducing or controlling tumor growth.
- the development of tumor vaccines is also the key research direction of current tumor immunotherapy.
- cytotoxic (CD8+) and helper (CD4+) T cells play a key role in tumor rejection. Therefore, the goal of most tumor vaccines is to induce cell-specific T cell responses.
- MHC I molecules are recognized by CD4+ T cells and are mainly located on the surface of special antigen-presenting cells (APC), including dendritic cells, B cells and macrophages. Exogenous proteins secreted by tumor cells or released by tumor lysis are captured by APCs.
- APC antigens are processed into polypeptide fragments and presented to CD4+ cells by MHC class II. The activated antigen-specific CD8+ cells eventually become cytotoxic T cells and lyse tumor cells.
- the ideal tumor-specific antigen should have strong immunogenicity and be expressed by tumor cells but not expressed in normal cells. Unfortunately, most tumor antigens are not sufficiently immunogenic to induce an effective immune response, and many tumor antigens are expressed in normal tissues to some extent, leading to immune tolerance in the body. Therefore, these tumor antigens naturally have the characteristics of weak immunogenicity, and the designed tumor vaccine must overcome the body's immune tolerance barriers and activate the immune response against tumor antigens.
- Tumor vaccines are mainly divided into whole cell vaccines, protein vaccines, peptide vaccines, virus vaccines and dendritic cell vaccines.
- DNA vaccines and RNA vaccines are still molecular vaccines, but use different expression systems.
- tumor antigen vaccines In the past, the relationship between tumor antigens and their clinical relevance was not very clear. Therefore, whole cells are used as tumor vaccines so that unknown tumor antigens can be provided to activate the immune system tumor antigens. In mouse tumor models, radiation-inactivated tumor cells are usually used to immunize mice to protect them from the inoculated tumor. But when the tumor cell vaccine was postponed to one week after the tumor cell inoculation, the vaccine lost its ability to protect mice. The clinical treatment response of tumor cell vaccine is relatively poor, and it is only suitable for the prevention of recurrence of tumor patients without special tumor antigens. For advanced patients, good results are rarely obtained in clinical research. In recent years, due to the progress in the recognition and analysis of tumor antigens, especially the in-depth understanding of the mechanism of T cell recognition of antigens, tumor antigen vaccines have basically replaced cell vaccines for tumor immunotherapy.
- Polypeptide and protein vaccines The antigenic polypeptide epitopes on the surface of MHC molecules recognized by T cells are generally 7-12 amino acids. Therefore, antigenic polypeptides can be mixed with immune adjuvants to achieve the purpose of loading empty MHC molecules in the body. So far, almost all peptide-based vaccines are MHC class I antigen-restricted peptides. There are some limitations in the application of peptide vaccines. The peptide vaccine used must match the patient’s MHC class I antigen molecules, which is so-called individualization. However, due to the different subtypes of the MHC class I molecules of different patients, the sequence of the tumor antigen peptides used is also different. This brings great difficulties to the clinical application of tumor antigen peptides.
- Recombinant molecular vaccines The application of tumor antigen protein vaccines can overcome this difficulty, but the use of protein alone cannot activate the body's immune response.
- Experimental studies in primates have confirmed that the best immune effect requires that the tumor protein is stranded with a strong immunogenic protein.
- an immune adjuvant For weak antigens to induce an effective immune response, an immune adjuvant must be used in combination to provide a non-specific signal to activate the immune system. Many immune adjuvants have certain toxicity and cannot be used in clinical practice. Therefore, antigen protein vaccines are mostly used. Coming in the form of reorganization.
- the method to enhance the immunogenicity of tumor proteins with recombinant forms is to recombine tumor antigens with cytokines such as GM-CSF and interleukins to form fusion proteins.
- cytokines such as GM-CSF and interleukins
- the recombination of weak tumor antigens with bacterial or viral antigens, toxins such as diphtheria toxin, pseudomonas toxin, etc. can significantly improve the antigenicity of tumor antigens, promote the phagocytosis and presentation of tumor antigens by DC, and has achieved certain effects.
- the method of separate recombination of tumor antigen and toxin has not yet achieved the desired effect so far.
- Dendritic cell vaccine For an effective T cell-mediated immune response, T cells need antigen to be presented and sensitize the initial T cells, and the sensitized T lymphocytes are re-stimulated. To initiate effective T cell-mediated tumor immunity, tumor antigen polypeptides derived from any part of the body must be recognized by T cells. Therefore, the presentation of antigen is a key step to obtain an effective immune response.
- the immune response stimulated by the vaccine mainly depends on the initial processing and further presentation of the antigen by the effective APC.
- the purpose of the present invention is to provide a recombinant virus vector, which can be used as a tumor vaccine and can be used to prevent or treat a variety of tumors.
- the recombinant viral vector comprises a polynucleotide encoding a tumor antigen.
- Tumor antigen refers to an antigenic substance that is newly emerged or overexpressed in the process of tumor occurrence and development.
- Tumor antigens include, but are not limited to, tumor-specific antigens, tumor-associated antigens, tissue differentiation antigens, proto-oncovirus antigens, and tumor-testis antigens (CT antigens).
- Tumor-Specific Antigens refers to antigenic substances that are only expressed in tumor cells and not in normal cells.
- mutant antigens especially the mutant products of proto-oncogenes and tumor suppressor genes, including ras and p53.
- Tumor-Associated Antigens (Tumor-Associated Antigens, TAA) refers to antigenic substances expressed in tumor cells and some normal cells.
- Tumor-testis antigens refer to antigenic substances expressed only in tumor cells and some germ cells. Such as NY-ESO-1, LAGE-1 and MAGE-A3.
- the tumor antigen is selected from one or more of lung cancer antigen, testicular cancer antigen, melanoma antigen, liver cancer antigen, breast cancer antigen, or prostate cancer antigen.
- the tumor antigens include but are not limited to alpha fetoprotein (AFP), carcinoembryonic antigen (CEA), mucin 1 (MUC1), melanoma-related antigen (Melanoma-associated antigen, MAGE), NY-ESO-1, LAGE-1, p53 and ras, etc.
- AFP alpha fetoprotein
- CEA carcinoembryonic antigen
- MUC1 mucin 1
- MAGE melanoma-related antigen
- NY-ESO-1 LAGE-1
- p53 and ras etc.
- the tumor antigen is selected from one or more of LAGE antigen, MAGE antigen or NY-ESO-1 antigen.
- the LAGE antigen is the LAGE-1 antigen
- the MAGE antigen is the MAGE-A3 antigen.
- the tumor antigens comprise LAGE-1 antigen, MAGE-A3 antigen and NY-ESO-1 antigen.
- the amino acid sequence of the LAGE-1 antigen is shown in SEQ ID NO: 1, and the encoding nucleic acid sequence is shown in SEQ ID NO: 2.
- the amino acid sequence of the MAGE-A3 antigen is shown in SEQ ID NO: 3, and the encoding nucleic acid sequence is shown in SEQ ID NO: 4.
- the amino acid sequence of the NY-ESO-1 antigen is shown in SEQ ID NO: 5, and the encoding nucleic acid sequence is shown in SEQ ID NO: 6.
- the tumor antigen further comprises a cholera toxin B subunit polypeptide.
- the amino acid sequence of the cholera toxin B subunit polypeptide is shown in SEQ ID NO: 7, and its encoding nucleic acid sequence is shown in SEQ ID NO: 8. Show.
- the amino acid sequence of the tumor antigen including the LAGE-1 antigen, the MAGE-A3 antigen and the NY-ESO-1 antigen is shown in SEQ ID NO: 9, and the encoding nucleic acid sequence is shown in SEQ ID NO: 10.
- the recombinant virus is a vaccinia virus, preferably a replicating vaccinia virus vector, such as a vaccinia virus Tiantan strain, such as 752-1 strain, or a non-replicating vaccinia virus vector, such as a modified vaccinia virus attenuated vaccine Ankara strain (Modified Vaccinia Ankara) , MVA).
- a replicating vaccinia virus vector such as a vaccinia virus Tiantan strain, such as 752-1 strain
- a non-replicating vaccinia virus vector such as a modified vaccinia virus attenuated vaccine Ankara strain (Modified Vaccinia Ankara) , MVA).
- Another object of the present invention is to provide an immune composition comprising a therapeutically effective amount of the recombinant viral vector according to the present invention, and a pharmaceutically acceptable carrier.
- Another object of the present invention is to provide a tumor vaccine comprising a therapeutically effective amount of the recombinant viral vector according to the present invention and a pharmaceutically acceptable carrier.
- Another object of the present invention is to provide a kit containing the recombinant viral vector and/or immune composition and/or tumor according to the present invention, and instructions for use thereof.
- the present invention also provides the use of the recombinant virus vector, immune composition and/or tumor vaccine according to the present invention in the preparation of drugs for treating or preventing tumors.
- the tumor is a malignant tumor.
- the malignant tumor is breast cancer or colon cancer.
- the present invention also provides a method for treating or preventing tumors, the method comprising administering to a subject in need a therapeutically effective amount of the recombinant viral vector, immune composition and/or tumor vaccine according to the present invention; preferably ,
- the tumor is a malignant tumor; more preferably, the malignant tumor is breast cancer or colon cancer.
- the recombinant virus vector provided by the present invention can stimulate tumor-specific immune response, effectively inhibit the growth of tumor cells, and prolong the survival time of tumor patients.
- Figure 1 and Figure 2 are the plasmid map and double restriction identification map of the shuttle vector vector pSC65-LMNB with LAGE-1, MAGE-A3 and NY-ESO-1 antigen coding sequences, respectively.
- FIG. 3 shows the 4T1-hNY-ESO-1 mouse tumor model in Example 4, and the tumor growth of each group of mice.
- Figure 4 shows the 4T1-hNY-ESO-1 mouse tumor model in Example 4, and the overall survival status of mice in each group.
- Figure 5 shows the CT26-MAGE-A3 mouse tumor model in Example 5. The tumor growth of each group of mice.
- Figure 6 shows the CT26-MAGE-A3 mouse tumor model in Example 5, and the overall survival status of mice in each group.
- Figure 7 shows the CT26-LAGE-1 mouse tumor model in Example 6, and the tumor growth of mice in each group.
- Figure 8 shows the CT26-LAGE-1 mouse tumor model in Example 6, and the overall survival status of mice in each group.
- Figure 9 shows the CT26-LAGE-1 mouse tumor model in Example 7, and the overall survival status of mice in each group.
- Figure 10 shows the 4T1-NY-ESO-1 mouse tumor model in Example 8, and the overall survival status of mice in each group.
- the eukaryotic expression vector pVKD1.0-LMNB expressing the triple fusion tumor antigens LAGE-1, MAGE-A3, NY-ESO-1 and the B subunit of cholera toxin was provided by Suzhou Industrial Park Viking Biotechnology Co., Ltd. (refer to CN109575142A) , Wherein the amino acid sequence of the LAGE-1 antigen is shown in SEQ ID NO: 1, and the encoding nucleic acid sequence is shown in SEQ ID NO: 2; the amino acid sequence of the MAGE-A3 antigen is shown in SEQ ID NO: 3.
- the coding nucleic acid sequence is shown in SEQ ID NO: 4; the amino acid sequence of the NY-ESO-1 antigen is shown in SEQ ID NO: 5, and the coding nucleic acid sequence is shown in SEQ ID NO: 6;
- the amino acid sequence of the cholera toxin B subunit polypeptide is shown in SEQ ID NO: 7, and its coding nucleic acid sequence is shown in SEQ ID NO: 8;
- the amino acid sequence of the LMNB fusion protein is shown in SEQ ID NO: 9, and its nucleic acid coding sequence is shown in SEQ ID NO: 10.
- Enzyme digestion system volume Plasmid pSC65-LMNB 3 ⁇ L, about 1 ⁇ g Sal I (Bao Biological, Item No. 1080A) 1 ⁇ L Kpn I (Bao Biological, Item No. 1068A) 1 ⁇ L Enzyme digestion buffer 1 ⁇ L ddH2O Make up to 10 ⁇ L
- the specific method for obtaining the recombinant vaccinia virus vector in 143B cells is as follows. On day 1, plate 143B cells on a 6-well cell culture plate (JET, TCP-010-006) ( CRL-8303), 1 ⁇ 10 6 /well, incubate overnight in a carbon dioxide cell incubator at 37°C. On the second day, add vaccinia virus wild strain 752-1 (provided by Beijing Biological Products) at 0.05 MOI (ie 5 ⁇ 10 4 PFU (plaque forming unit)/well), and then place it in a 37°C carbon dioxide cell incubator Incubate for two hours during which the shuttle vector/transfection reagent complex is prepared.
- the shuttle vector is pSC65-LMNB obtained in Example 1, the transfection reagent is Turbofect (Thermo Fisher Scientific, R0531), and the transfection dosage and compounding method can be found in the transfection reagent manual.
- the 143B cell supernatant was changed to 2 mL/well of DMEM maintenance medium containing 2% fetal bovine serum (FBS), and then the shuttle vector/transfection reagent complex was added.
- FBS fetal bovine serum
- Example 3 Amplification preparation and titration of recombinant vaccinia virus vector rvv-LMNB
- the recombinant vaccinia virus vector rvv-LMNB constructed in Example 2 and the wild strain of vaccinia virus were respectively placed in Vero cells ( CCL-81) amplification, the amplification method is as follows.
- the cells were scraped and collected, centrifuged at 1800g for 5 minutes, and the supernatant was removed.
- the ultrasonic conditions are: 50 watts, 5 seconds ultrasonic / 5 second interval, 15 minutes in total.
- the amplified vaccinia virus was titrated on Vero cells, and the specific method is as follows.
- Table 2 shows the titration results of the vaccinia virus vector.
- Vaccinia virus Potency (PFU/mL) Vaccinia virus wild type rvv-wt 1.5 ⁇ 10 8 Recombinant vaccinia virus rvv-LMNB 1.0 ⁇ 10 8
- mice in the control group all developed tumors and grew rapidly on the 12th day after the tumor was attacked (that is, after tumor inoculation).
- the tumor growth of the mice in the rvv-LMNB treatment group was slower.
- the average tumor size of the mice in the treatment group was significantly smaller than that in the control group. The results show that the vaccinia virus vector vaccine rvv-LMNB can inhibit the growth of tumors with NY-ESO-1 expression.
- the survival curve results of the survival status of the mice are shown in Figure 4.
- the overall survival of the mice in the vaccinia virus vector vaccine rvv-LMNB treatment group (median OS 40 days) is better than that of the control mice (median OS 36 days, p ⁇ 0.05).
- the results indicate that the vaccinia virus vector vaccine rvv-LMNB can improve the survival of mice with tumors expressing NY-ESO-1.
- mice in each group The tumor growth of immunized mice in each group is shown in Figure 5.
- All mice in the control group developed tumors and grew rapidly on the 15th day after tumor inoculation.
- the average tumor size of the mice in the treatment group was significantly smaller than that in the control group.
- the results show that the vaccinia virus vector vaccine rvv-LMNB can inhibit the growth of tumors with MAGE-A3 expression.
- the survival curve results of the survival status of the mice are shown in Figure 6.
- the overall survival of the mice in the vaccinia virus vector vaccine rvv-LMNB treatment group (median OS 40 days) is better than that of the control mice (median OS 33 days, p ⁇ 0.05).
- the results indicate that the vaccinia virus vector vaccine rvv-LMNB can improve the survival of mice with tumors expressing MAGE-A3.
- the survival curve results of the survival status of the mice are shown in Figure 8.
- the overall survival of the mice in the vaccinia virus vector vaccine rvv-LMNB treatment group (median OS 58 days) is better than that of the control mice (median OS 51 days, p ⁇ 0.05).
- the results show that the vaccinia virus vector vaccine rvv-LMNB can improve the survival of mice with tumors expressing LAGE-1.
- mice 20 female BAL B/c mice aged 6-8 weeks were purchased from the Animal Experiment Center of Soochow University and kept in the SPF animal room of the Animal Experiment Center of Soochow University. On day 0, all mice were subcutaneously inoculated with tumor cells expressing LAGE-1 tumor antigen CT26-LAGE-1 stably transfected cell line (provided by Suzhou Industrial Park Weida Biotechnology Co., Ltd.), the inoculation dose was 1 ⁇ 10 5 cells per mouse, then randomly divided into 2 groups.
- LAGE-1 tumor antigen CT26-LAGE-1 stably transfected cell line provided by Suzhou Industrial Park Weida Biotechnology Co., Ltd.
- the proteome mouse protein vaccine LMNB was given (the specific preparation method and vaccination method are as described in Example 8 and Example 9 of Chinese Invention Patent Application CN109575141A) After vaccination, protein vaccines are fully emulsified with complete Freund's adjuvant (CFA) or incomplete Freund's adjuvant (IFA), and then injected subcutaneously on the back, 10 ⁇ g/mouse.
- CFA complete Freund's adjuvant
- IFA incomplete Freund's adjuvant
- mice in the vaccinia group were inoculated with the vaccinia virus vector prepared in Example 3 (the specific vaccination schedule is shown in Table 6). Continuous observation and measurement of tumor growth after inoculation.
- the survival curve results of the survival status of the mice are shown in Figure 9.
- the overall survival of the mice in the vaccinia virus vector vaccine rvv-LMNB treatment group (median OS 58 days) is better than that of the mice in the protein group (median OS 51 days, p ⁇ 0.05).
- the results show that the vaccinia virus vector vaccine rvv-LMNB can improve the survival of mice with tumors expressing LAGE-1.
- mice 20 female BAL B/c mice aged 6-8 weeks were purchased from the Animal Experiment Center of Soochow University and kept in the SPF animal room of the Animal Experiment Center of Soochow University. On day 0, all mice were subcutaneously inoculated with tumor cells expressing NY-ESO-1 tumor antigen 4T1-hNY-ESO-1 stably transfected cell line (provided by Suzhou Industrial Park Weike Biotechnology Co., Ltd.), inoculation dose 2 ⁇ 10 5 cells/head, and then randomly divided into 2 groups.
- tumor cells expressing NY-ESO-1 tumor antigen 4T1-hNY-ESO-1 stably transfected cell line (provided by Suzhou Industrial Park Weike Biotechnology Co., Ltd.), inoculation dose 2 ⁇ 10 5 cells/head, and then randomly divided into 2 groups.
- the proteome mouse protein vaccine LMNB was given (the specific preparation method and vaccination method are as described in Example 8 and Example 9 of Chinese Invention Patent Application CN109575141A) After vaccination, protein vaccines are fully emulsified with complete Freund's adjuvant (CFA) or incomplete Freund's adjuvant (IFA), and then injected subcutaneously on the back, 10 ⁇ g/mouse.
- CFA complete Freund's adjuvant
- IFA incomplete Freund's adjuvant
- mice in the vaccinia group were inoculated with the vaccinia virus vector prepared in Example 3 (the specific vaccination schedule is shown in Table 7). Continuous observation and measurement of tumor growth after inoculation.
- the survival curve results of the survival status of the mice are shown in Figure 10.
- the overall survival of the mice in the vaccinia virus vector vaccine rvv-LMNB treatment group (median OS 40 days) is better than that of the control mice (median OS 36 days, p ⁇ 0.05).
- the results indicate that the vaccinia virus vector vaccine rvv-LMNB can improve the survival of mice with tumors expressing NY-ESO-1.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
一种重组病毒载体、包含其的免疫组合物以及用途。所述重组病毒载体包含编码肿瘤抗原的多核苷酸,所述肿瘤抗原选自LAGE抗原、MAGE抗原或NY-ESO-1抗原中的一种或多种。重组病毒载体疫苗能够激发肿瘤特异性免疫应答,有效抑制肿瘤细胞生长,延长肿瘤患者的生存时间。
Description
本发明属于分子生物学和免疫学领域。具体地,本发明涉及一种重组病毒载体、包含其的免疫组合物以及用途,特别地,本发明涉及一种肿瘤治疗性疫苗。
随着肿瘤生物学和免疫学的发展,肿瘤免疫治疗取得了长足的进步,逐步成为当前肿瘤治疗的重要发展方向。特别是伴随PD-1/PD-L1免疫疗法的巨大成功,开发肿瘤免疫疗法成为当前肿瘤治疗新兴的热点。
肿瘤疫苗通过激发体内的针对肿瘤的特异性免疫应答,活化产生庞大的免疫细胞,来杀伤和控制肿瘤细胞的生长,从而达到减小或控制肿瘤生长的效果。肿瘤疫苗的开发也是当前肿瘤免疫治疗的重点研究方向。
研究表明细胞毒(CD8+)和辅助(CD4+)T细胞在肿瘤排斥反应中起了关键的作用。因此,大多数肿瘤疫苗的目标都致力于诱导细胞的特异性的T细胞反应。肿瘤细胞在合成肿瘤抗原的过程中,分解的多肽通过MHCI类分子被提呈致肿瘤细胞表面激活CD8+T细胞。MHC II类分子为CD4+T细胞所识别,主要位于特殊的抗原提呈细胞(APC)表面,包括树突状细胞、B细胞和巨噬细胞。肿瘤细胞分泌或肿瘤溶解释放外源性蛋白被APCs俘获。在APC内,抗原被加工成多肽片断并由II类MHC提呈给CD4+细胞。激活的抗原特异性CD8+细胞最终成为细胞毒T细胞并溶解肿瘤细胞。
理想的肿瘤特异性抗原应具有较强的免疫原性,为肿瘤细胞所表达但不表达于正常的细胞。不幸的是,大多数肿瘤抗原都没有足够的免疫原性以诱导有效的免疫反应,而且,许多肿瘤抗原在某种程度上表达于正常的组织,从而导致体内存在免疫耐受。因此,这些肿瘤抗原天然存在免疫原性弱的特点,所设计的肿瘤疫苗就必须要克服机体的免疫耐受障碍,激活针对肿瘤抗原的免疫应答产生。
肿瘤疫苗主要分为全细胞疫苗、蛋白疫苗、多肽疫苗、病毒疫苗和树突状细胞疫苗。而DNA疫苗和RNA疫苗实际上仍属于分子疫苗,只是采用了不同的表达系统。
细胞疫苗:过去,对肿瘤抗原与其临床的相关性方面并不十分清楚,因此采用全细胞作为肿瘤疫苗,以便可以提供那些未知的肿瘤抗原来激活免疫系统肿瘤抗原。在小鼠肿瘤模型中,通常使用辐射灭活的肿瘤细胞免 疫小鼠,以保护小鼠免受接种的肿瘤的侵袭。但当肿瘤细胞疫苗使用的时间推迟到接种肿瘤细胞后一周时,疫苗就失去了保护小鼠的能力。肿瘤细胞疫苗的临床治疗反应比较差,仅仅适用于无特殊肿瘤抗原的肿瘤病人的预防复发。对于进展期病人在临床研究方面很少获得良好效果。近年来,由于在识别分析肿瘤抗原方面的进展,特别是T细胞识别抗原的机制的深入了解,肿瘤抗原疫苗已基本取代细胞疫苗被用于肿瘤的免疫治疗。
多肽和蛋白疫苗:T细胞识别MHC分子表面的抗原多肽表位一般为7-12个氨基酸,因此,抗原多肽可以与免疫佐剂混合应用以达到在体内装载于空虚的MHC分子的目的。到目前为止,几乎所有的以多肽为基础的疫苗都是MHC I类抗原限制性多肽。多肽疫苗应用有一些限制。所应用的多肽疫苗必需与病人的MHC I类抗原分子相匹配,即所谓的个体化,但由于不同的病人MHC I类分子的亚型不同,所使用的肿瘤抗原多肽的序列也不同,因而这给肿瘤抗原多肽的临床应用带来很大的困难。
重组分子疫苗:肿瘤抗原蛋白疫苗的应用可以克服这种困难,但是单纯使用蛋白并不能激活机体的免疫反应。灵长类动物试验研究证实最佳的免疫效果需要将肿瘤蛋白与强免疫原性蛋白相绞联。弱抗原要诱导出有效的免疫反应,就必须联合使用免疫佐剂,提供一个非特异性的信号以激活免疫系统,许多免疫佐剂都有一定的毒性而不能应用于临床,所以抗原蛋白疫苗大都是以重组形式出现的。
用重组形式增强肿瘤蛋白的免疫原性的方法就是将肿瘤抗原与细胞因子,如GM-CSF、白细胞介素等重组形成融合蛋白。肿瘤弱抗原与细菌或病毒抗原、毒素如白喉毒素、假单胞菌毒素等的重组可以明显提高肿瘤抗原的抗原性,促进DC对肿瘤抗原的吞噬提呈,取得了一定的效果。但肿瘤抗原与毒素的单独重组的方法到目前为止仍然还没有达到理想的效果。
树突状细胞疫苗:对于有效的T细胞介导的免疫反应,T细胞需要抗原被提呈并致敏初始T细胞,致敏的T淋巴细胞获得再刺激。要启动有效的T细胞介导的肿瘤免疫,来源于体内任何部位的肿瘤抗原多肽必须被T细胞所识别。因此,抗原的提呈是获得有效免疫反应的关键性步骤。疫苗刺激的免疫反应主要依赖于有效的APC对抗原的初加工和进一步的提呈。
因此,为了提高肿瘤抗原的免疫原性,激发肿瘤特异性免疫应答,从根本上治愈肿瘤,本领域中需要开发出新的肿瘤疫苗。
发明内容
本发明的目的是提供一种重组病毒载体,该重组病毒载体可以作为肿瘤疫苗,可以用于预防或治疗多种肿瘤。
在本发明的一个实施方案中,所述重组病毒载体包含编码肿瘤抗原的多核苷酸。
为了本发明的目的以下定义下列术语。
“肿瘤抗原”是指在肿瘤发生、发展过程中新出现或过度表达的抗原物质。肿瘤抗原包括但不限于肿瘤特异性抗原、肿瘤相关抗原、组织分化抗原、原癌病毒抗原和肿瘤-睾丸抗原(cancer-testis antigens,CT抗原)等。
“肿瘤特异性抗原”(Tumor-Specific Antigens,TSA)是指仅在肿瘤细胞中表达,不在正常细胞中表达的抗原物质。例如突变的抗原,特别是原癌基因和肿瘤抑制基因的突变产物,包括ras和p53等。
“肿瘤相关抗原”(Tumor-Associated Antigens,TAA)是指在肿瘤细胞中和一些正常细胞中表达的抗原物质。
肿瘤-睾丸抗原是指只在肿瘤细胞和一些生殖细胞中表达的抗原物质。例如NY-ESO-1、LAGE-1和MAGE-A3等。
在本发明的一个实施方案中,所述肿瘤抗原选自肺癌抗原、睾丸癌抗原、黑色素瘤抗原、肝癌抗原、乳腺癌抗原或前列腺癌抗原中的一种或多种。
在本发明的一个实施方案中,所述肿瘤抗原包括但不限于甲胎蛋白(alpha fetoprotein,AFP)、癌胚抗原(carcinoembryonic antigen,CEA)、粘蛋白1(mucins,MUC1)、黑色素瘤相关抗原(Melanoma-associated antigen,MAGE)、NY-ESO-1、LAGE-1、p53和ras等。
在本发明的一个实施方案中,所述肿瘤抗原选自LAGE抗原、MAGE抗原或NY-ESO-1抗原中的一种或多种。优选地,LAGE抗原为LAGE-1抗原,MAGE抗原为MAGE-A3抗原。进一步优选地,所述肿瘤抗原包含LAGE-1抗原、MAGE-A3抗原和NY-ESO-1抗原。优选地,所述LAGE-1抗原的氨基酸序列如SEQ ID NO:1所示,其编码核酸序列如SEQ ID NO:2所示。优选地,所述MAGE-A3抗原的氨基酸序列如SEQ ID NO:3所示,其编码核酸序列如SEQ ID NO:4所示。优选地,所述NY-ESO-1抗原的氨基酸序列如SEQ ID NO:5所示,其编码核酸序列如SEQ ID NO:6所示。优选地,所述肿瘤抗原还包含霍乱毒素B亚单位多肽,优选地,所述霍乱毒素B亚单位多肽的氨基酸序列如SEQ ID NO:7所示,其编码核酸序列如SEQ ID NO:8所示。优选地,包含LAGE-1抗原、MAGE-A3抗原和NY-ESO-1抗原的肿瘤抗原的氨基酸序列如SEQ ID NO:9所示,其编码核酸序列如SEQ ID NO:10所示。
优选地,重组病毒是痘苗病毒,优选为复制型痘苗病毒载体,例如痘苗病毒天坛株,例如752-1株,或者为非复制型痘苗病毒载体,例如痘苗病 毒减毒疫苗安卡拉株(Modified Vaccinia Ankara,MVA)。
本发明的另一目的是提供一种免疫组合物,所述免疫组合物包含治疗有效量的根据本发明的重组病毒载体,以及药学上可接受的载体。
本发明的另一目的是提供一种肿瘤疫苗,所述肿瘤疫苗包含治疗有效量的根据本发明的重组病毒载体,以及药学上可接受的载体。
本发明的另一目的是提供一种药盒,所述药盒包含根据本发明的重组病毒载体和/或免疫组合物和/或肿瘤,以及其使用说明。
本发明还提供了根据本发明的重组病毒载体、免疫组合物和/或肿瘤疫苗在制备治疗或预防肿瘤的药物中的用途。优选地,所述肿瘤为恶性肿瘤。优选地,所述恶性肿瘤为乳腺癌或结肠癌。
本发明还提供了一种用于治疗或预防肿瘤的方法,所述方法包括给予有需要的受试者治疗有效量的根据本发明的重组病毒载体、免疫组合物和/或肿瘤疫苗;优选地,所述肿瘤为恶性肿瘤;更优选地,所述恶性肿瘤为乳腺癌或结肠癌。
本发明提供的重组病毒载体能够激发肿瘤特异性免疫应答,有效抑制肿瘤细胞生长,延长肿瘤患者的生存时间。
附图的简要说明
以下,结合附图来详细说明本发明的实施方案,其中:
图1和图2分别是带有LAGE-1、MAGE-A3和NY-ESO-1抗原编码序列的穿梭载体载体pSC65-LMNB的质粒图谱和双酶切鉴定图。
图3为实施例4中的4T1-hNY-ESO-1小鼠肿瘤模型,各组小鼠肿瘤生长情况。
图4为实施例4中的4T1-hNY-ESO-1小鼠肿瘤模型,各组小鼠总体存活状况。
图5为实施例5中的CT26-MAGE-A3小鼠肿瘤模型,各组小鼠肿瘤生长情况。
图6为实施例5中的CT26-MAGE-A3小鼠肿瘤模型,各组小鼠总体存活状况。
图7为实施例6中的CT26-LAGE-1小鼠肿瘤模型,各组小鼠肿瘤生长情况。
图8为实施例6中的CT26-LAGE-1小鼠肿瘤模型,各组小鼠总体存活状况。
图9为实施例7中的CT26-LAGE-1小鼠肿瘤模型,各组小鼠总体存活状况。
图10为实施例8中的4T1-NY-ESO-1小鼠肿瘤模型,各组小鼠总体存活状况。
实施发明的最佳方式
下面结合实施例进一步说明本发明,应当理解,实施例仅用于进一步说明和阐释本发明,并非用于限制本发明。
除非另外定义,本说明书中有关技术的和科学的术语与本领域内的技术人员所通常理解的意思相同。虽然在实验或实际应用中可以应用与此间所述相似或相同的方法和材料,本文还是在下文中对材料和方法做了描述。在相冲突的情况下,以本说明书包括其中定义为准,另外,材料、方法和例子仅供说明,而不具限制性。
实施例1 穿梭载体pSC65-LMNB构建
表达三联融合肿瘤抗原LAGE-1、MAGE-A3、NY-ESO-1以及霍乱毒素B亚单位的真核表达载体pVKD1.0-LMNB由苏州工业园区唯可达生物科技有限公司提供(参考CN109575142A),其中,所述LAGE-1抗原的氨基酸序列如SEQ ID NO:1所示,其编码核酸序列如SEQ ID NO:2所示;所述MAGE-A3抗原的氨基酸序列如SEQ ID NO:3所示,其编码核酸序列如SEQ ID NO:4所示;所述NY-ESO-1抗原的氨基酸序列如SEQ ID NO:5所示,其编码核酸序列如SEQ ID NO:6所示;所述霍乱毒素B亚单位多肽的氨基酸序列如SEQ ID NO:7所示,其编码核酸序列如SEQ ID NO:8所示;LMNB融合蛋白氨基酸如SEQ ID NO:9所示,其核酸编码序列如SEQ ID NO:10所示。用Sal I和Kpn I从pVKD1.0-LMNB切下含有LMNB片段,然后转移至穿梭载体pSC65(addgene,货号:30327)上的多克隆位点Sal I与Kpn I之间,构建成可表达融合蛋白抗原的穿梭载体pSC65-LMNB(质粒图谱如图1),经测序鉴定正确后入库。用限制内切酶Sal I与Kpn I鉴定载体pSC65-LMNB(酶切体系如表1),其酶切验证图谱如图2所示。
表1 质粒pSC65-LMNB的酶切鉴定体系(37℃酶切2小时)
酶切体系 | 体积 |
质粒pSC65-LMNB | 3μL,约1μg |
Sal I(宝生物,货号1080A) | 1μL |
Kpn I(宝生物,货号1068A) | 1μL |
酶切缓冲液 | 1μL |
ddH2O | 补至10μL |
实施例2 重组痘苗病毒载体rvv-LMNB构建
在143B细胞中获得重组痘苗病毒载体,具体方法如下。第1天,在6孔细胞培养板(JET,TCP-010-006)铺143B细胞(
CRL-8303),1×10
6/孔,于37℃二氧化碳细胞培养箱中过夜孵育。第二天,以0.05MOI(即5×10
4PFU(空斑形成单位)/孔)加入痘苗病毒野生株752-1(由北京生物制品所提供),然后置于37℃二氧化碳细胞培养箱中孵育两个小时,期间准备穿梭载体/转染试剂复合物。其中穿梭载体为实施例1中获得的pSC65-LMNB,转染试剂为Turbofect(Thermo Fisher Scientific,R0531),转染剂量与复合方法可参见转染试剂说明书。复合体系完成后,将143B细胞上清换为2mL/孔的含2%胎牛血清(FBS)的DMEM维持培养基,然后加入穿梭载体/转染试剂复合物。转染48小时后,去上清,收集细胞,并在0.5mL维持培养基中重悬,反复冻融三次,然后将重组细胞裂解物接入新的143B细胞上(含50μg/mL BrdU),37℃孵育1到2天。期间观察细胞病变,待病毒噬斑出现合适数量时(低于20空斑/孔),进行单斑纯化。
单斑纯化
将2%低熔点琼脂糖微波炉加热(中高火2分钟左右)至沸,转移至45℃水浴降温并防止其凝固。
吸取适量2×维持培养液(1mL/孔),按体积比1:50加入X-gal储存液,在45℃水浴中预热。
按等体积比例混合低熔点琼脂糖与含X-gal的2×维持培养液,制成铺斑固体培养基,去细胞上清,小心加入铺斑固体培养基,然后转移至4℃冰箱凝固10分钟,期间不要动6孔板,防止凝固不均匀。
待完全凝固后,转移6孔板至37℃细胞培养箱中孵育2至4小时(有时过夜),直至蓝斑出现。
待蓝斑出现后,用1mL枪头(预先用剪刀将枪头剪平)优先挑取分散较好的,颜色较深的蓝斑,挑取时一定要将固体培养基下面的细胞层挑到,每孔挑取若干个蓝斑,分别转移至含0.5mL维持培养液的Ep管中。
振荡混匀含病毒的Ep管,反复冻融三次(-80℃冰箱约5分钟,室温约2分钟),最后振荡混匀,-80℃冻存。
重复六轮单斑纯化,直至纯度至100%。
实施例3 重组痘苗病毒载体rvv-LMNB扩增制备与滴定
前一天,准备汇集度100%的Vero单层细胞(1×10
7细胞/皿),共10皿。
去上清,换为维持培养基,将待扩增的痘病毒接种到细胞上(0.01PFU/细胞),37℃培养箱孵育2-3天,观察可见明显的细胞病变。
将细胞刮下并收集,1800g离心5分钟,去上清。
用5mL维持培养基进行重悬,在冰上用超声波细胞粉粹机超声,超声条件为:50瓦,5秒超声/5秒间隔,共15分钟。
反复冻融两次(-80℃冰箱约5分钟,室温约2分钟),最后振荡混匀;
在二级生物安全柜中进行分装至1.5mL离心管中,1mL/支,-80℃冻存。
扩增制备好的痘苗病毒在Vero细胞上进行感染效价滴定,具体方法如下。
前一天,在24孔板中,准备汇集度100%的Vero细胞,3×10
5/孔。
去上清,每孔添加200μL维持培养液,以防止细胞干涸。
取100μL待测痘病毒加入900μL维持培养基,十倍稀释,连续稀释10
1,10
2,10
3,直到10
9倍。注意:进行稀释时,因为由高浓度向低浓度稀释,每次向低浓度稀释应更换枪头。
从病毒浓度由小到大(10
9,10
8,……10
4)添加到24孔板中,每孔400μL稀释液,两个重复,连续测定6个稀释倍数。将添加完的24孔板放入37℃细胞培养箱中孵育2天。
显微镜下数出病毒蚀斑的数目,多于20的,记为20+。将可以数出的20(含)以内的蚀斑数目两复孔求平均×2.5(1000μL/400μL)×相应孔的稀释倍数,即为重组病毒滴度(PFU/mL)。
痘苗病毒载体效价滴定结果如表2所示。
表2 痘苗病毒载体效价滴定
痘苗病毒 | 效价(PFU/mL) |
痘苗病毒野生型rvv-wt | 1.5×10 8 |
重组痘苗病毒rvv-LMNB | 1.0×10 8 |
实施例4 肿瘤治疗实验1
从苏州大学动物实验中心购买20只6-8周龄的雌性BAL B/c小鼠,并饲养于苏州大学动物实验中心SPF级动物房中。在第0天,所有小鼠皮下接种表达NY-ESO-1肿瘤抗原的肿瘤细胞4T1-hNY-ESO-1稳定转染细胞系(由苏州工业园区唯可达生物科技有限公司提供),接种剂量为2×10
5细胞/只,然后随机分成2两组。在肿瘤细胞接种后第1天,第14天和第28天给相应小鼠小腿胫骨前肌接种实施例3中制备的痘苗病毒载体(具体疫苗接种规划 如表3)。接种后连续观察并测量肿瘤生长情况。按照以下公式计算肿瘤体积:肿瘤体积(mm
3)=长×宽
2/2。当小鼠肿瘤体积超过2000mm
3时,对小鼠处死。
表3 实验动物分组与疫苗接种规划
各组免疫小鼠肿瘤生长情况如图3所示。其中,对照组小鼠在攻瘤后(即肿瘤接种后)第12天全部出现肿瘤,并迅速生长。与未治疗的对照组相比,rvv-LMNB治疗组小鼠肿瘤生长较慢。而且,在小鼠攻瘤后第21天,治疗组小鼠肿瘤平均大小显著小于对照组。结果表明痘苗病毒载体疫苗rvv-LMNB能抑制带有NY-ESO-1表达的肿瘤生长。
小鼠存活状况的生存曲线结果如图4所示,痘苗病毒载体疫苗rvv-LMNB治疗组小鼠总体生存(OS中位数40天)优于对照组小鼠(OS中位数36天,p<0.05)。结果表明痘苗病毒载体疫苗rvv-LMNB能提高患有表达NY-ESO-1肿瘤的小鼠生存。
实施例5 肿瘤治疗实验2
从苏州大学动物实验中心购买20只6-8周龄的雌性BAL B/c小鼠,并饲养于苏州大学动物实验中心SPF级动物房中。在第0天,所有小鼠皮下接种表达MAGE-A3肿瘤抗原的肿瘤细胞CT26-MAGE-A3稳定转染细胞系(由苏州工业园区唯可达生物科技有限公司提供),接种剂量为2×10
5细胞/只,然后随机分成2两组。在肿瘤细胞接种后第1天,第14天和第28天给相应小鼠小腿胫骨前肌接种实施例3中制备的痘苗病毒载体(具体疫苗接种规划如表4)。接种后连续观察并测量肿瘤生长情况。按照以下公式计算肿瘤体积:肿瘤体积(mm
3)=长×宽
2/2。当小鼠肿瘤体积超过10000mm
3时,对小鼠处死。
表4 实验动物分组与疫苗接种规划
各组免疫小鼠肿瘤生长情况如图5所示。其中,对照组小鼠在肿瘤接种后第15天全部出现肿瘤,并迅速生长。在小鼠攻瘤后第30天,治疗组小鼠肿瘤平均大小显著小于对照组。结果表明痘苗病毒载体疫苗rvv-LMNB能抑制带有MAGE-A3表达的肿瘤生长。
小鼠存活状况的生存曲线结果如图6所示,痘苗病毒载体疫苗rvv-LMNB治疗组小鼠总体生存(OS中位数40天)优于对照组小鼠(OS中位数33天,p<0.05)。结果表明痘苗病毒载体疫苗rvv-LMNB能提高患有表达MAGE-A3肿瘤的小鼠生存。
实施例6 肿瘤治疗实验3
从苏州大学动物实验中心购买20只6-8周龄的雌性BAL B/c小鼠,并饲养于苏州大学动物实验中心SPF级动物房中。在第0天,所有小鼠皮下接种表达LAGE-1肿瘤抗原的肿瘤细胞CT26-LAGE-1稳定转染细胞系(由苏州工业园区唯可达生物科技有限公司提供),接种剂量为1×10
5细胞/只,然后随机分成2两组。在肿瘤细胞接种后第1天,第14天和第28天给相应小鼠小腿胫骨前肌接种实施例3中制备的痘苗病毒载体(具体疫苗接种规划如表5)。接种后连续观察并测量肿瘤生长情况。按照以下公式计算肿瘤体积:肿瘤体积(mm
3)=长×宽
2/2。当小鼠肿瘤体积超过10000mm
3时,对小鼠处死。
表5 实验动物分组与疫苗接种规划
各组免疫小鼠肿瘤生长情况如图7所示。在攻瘤后第26天,对照组小鼠肿瘤生长迅速,并显著大于治疗组小鼠,一直持续到第50天。结果表明痘苗病毒载体疫苗rvv-LMNB能抑制带有LAGE-1表达的肿瘤生长。
小鼠存活状况的生存曲线结果如图8所示,痘苗病毒载体疫苗rvv-LMNB治疗组小鼠总体生存(OS中位数58天)优于对照组小鼠(OS中位数51天,p<0.05)。结果表明痘苗病毒载体疫苗rvv-LMNB能提高患有表达LAGE-1肿瘤的小鼠生存。
实施例7 肿瘤治疗实验4
从苏州大学动物实验中心购买20只6-8周龄的雌性BAL B/c小鼠,并饲养于苏州大学动物实验中心SPF级动物房中。在第0天,所有小鼠皮下接种表达LAGE-1肿瘤抗原的肿瘤细胞CT26-LAGE-1稳定转染细胞系(由苏州工业园区唯可达生物科技有限公司提供),接种剂量为1×10
5细胞/只,然后随机分成2两组。在肿瘤细胞接种后第1天,第14天和第28天,给蛋白组小鼠蛋白疫苗LMNB(具体制备方式和接种方式如中国发明专利申请CN109575141A的实施例8和实施例9中所述)接种,蛋白疫苗均在与完全弗氏佐剂(CFA)或不完全弗氏佐剂(IFA)充分乳化后,背部皮下注射,10μg/只。相应地,在肿瘤细胞接种后第1天,第14天和第28天,痘苗组小鼠小腿胫骨前肌接种实施例3中制备的痘苗病毒载体(具体疫苗接种规划如表6)。接种后连续观察并测量肿瘤生长情况。按照以下公式计算肿瘤体积:肿瘤体积(mm
3)=长×宽
2/2。当小鼠肿瘤体积超过10000mm
3时,对小鼠处死。
表6 实验动物分组与疫苗接种规划
小鼠存活状况的生存曲线结果如图9所示,痘苗病毒载体疫苗rvv-LMNB治疗组小鼠总体生存(OS中位数58天)优于蛋白组小鼠(OS中位数51天,p<0.05)。结果表明痘苗病毒载体疫苗rvv-LMNB能提高患有表达LAGE-1肿瘤的小鼠生存。
实施例8 肿瘤治疗实验5
从苏州大学动物实验中心购买20只6-8周龄的雌性BAL B/c小鼠,并饲养于苏州大学动物实验中心SPF级动物房中。在第0天,所有小鼠皮下接种表达NY-ESO-1肿瘤抗原的肿瘤细胞4T1-hNY-ESO-1稳定转染细胞系(由苏州工业园区唯可达生物科技有限公司提供),接种剂量为2×10
5细胞/只,然后随机分成2两组。在肿瘤细胞接种后第1天,第14天和第28天,给蛋白组小鼠蛋白疫苗LMNB(具体制备方式和接种方式如中国发明专利申请CN109575141A的实施例8和实施例9中所述)接种,蛋白疫苗均在与完全弗氏佐剂(CFA)或不完全弗氏佐剂(IFA)充分乳化后,背部皮下注射,10μg/只。相应地,在肿瘤细胞接种后第1天,第14天和第28天,痘苗组小鼠小腿胫骨前肌接种实施例3中制备的痘苗病毒载体(具体疫苗接种规划如表7)。接种后连续观察并测量肿瘤生长情况。按照以下公式计算肿瘤体积:肿瘤体积(mm
3)=长×宽
2/2。当小鼠肿瘤体积超过2000mm
3时,对小鼠处死。
表7 实验动物分组与疫苗接种规划
小鼠存活状况的生存曲线结果如图10所示,痘苗病毒载体疫苗rvv-LMNB治疗组小鼠总体生存(OS中位数40天)优于对照组小鼠(OS中位数36天,p<0.05)。结果表明痘苗病毒载体疫苗rvv-LMNB能提高患有表达NY-ESO-1肿瘤的小鼠生存。
尽管本发明已进行了一定程度的描述,明显地,在不脱离本发明的精神和范围的条件下,可进行各个条件的适当变化。可以理解,本发明不限于所述实施方案,而归于权利要求的范围,其包括所述每个因素的等同替换。
Claims (12)
- 一种重组病毒载体,所述重组病毒载体包含编码肿瘤抗原的多核苷酸,所述肿瘤抗原选自LAGE抗原、MAGE抗原或NY-ESO-1抗原中的一种或多种。
- 根据权利要求1所述的重组病毒载体,其中,所述LAGE抗原为LAGE-1抗原;优选地,所述LAGE-1抗原的氨基酸序列如SEQ ID NO:1所示;优选地,其编码核酸序列如SEQ ID NO:2所示。
- 根据权利要求1或2所述的重组病毒载体,其中,所述MAGE抗原为MAGE-A3抗原;优选地,所述MAGE-A3抗原的氨基酸序列如SEQ ID NO:3所示;优选地,其编码核酸序列如SEQ ID NO:4所示。
- 根据权利要求1至3任一项所述的重组病毒载体,其中,所述NY-ESO-1抗原的氨基酸序列如SEQ ID NO:5所示;优选地,其编码核酸序列如SEQ ID NO:所示6。
- 根据权利要求1至4任一项所述的重组病毒载体,其中,所述肿瘤抗原还包含霍乱毒素B亚单位多肽;优选地,所述霍乱毒素B亚单位多肽的氨基酸序列如SEQ ID NO:7所示;优选地,其编码核酸序列如SEQ ID NO:8所示。
- 根据权利要求1至5任一项所述的重组病毒载体,其中,所述肿瘤抗原包含LAGE-1抗原、MAGE-A3抗原和NY-ESO-1抗原;优选地,所述肿瘤抗原的氨基酸序列如SEQ ID NO:9所示;优选地,其编码核酸序列如SEQ ID NO:10所示。
- 根据权利要求1至6任一项所述的重组病毒载体,其中,所述重组病毒是痘苗病毒载体,优选为复制型痘苗病毒载体,例如痘苗病毒天坛株,例如752-1株,或者为非复制型痘苗病毒载体,例如痘苗病毒减毒疫苗安卡拉株(Modified Vaccinia Ankara,MVA)。
- 一种免疫组合物,其包含治疗有效量的根据权利要求1-7中任一项所述的重组病毒载体,以及药学上可接受的载体。
- 一种肿瘤疫苗,其包含治疗有效量的根据权利要求1-7中任一项所述的重组病毒载体,以及药学上可接受的载体。
- 一种药盒,其包含根据权利要求1-7中任一项所述的重组病毒载体、根据权利要求8所述的免疫组合物或根据权利要求9所述的肿瘤疫苗,以及其使用说明。
- 根据权利要求1-7中任一项所述的重组病毒载体、根据权利要求8所述的免疫组合物或根据权利要求9所述的肿瘤疫苗在制备治疗或预防肿 瘤的药物中的用途;优选地,所述肿瘤为恶性肿瘤;更优选地,所述恶性肿瘤为乳腺癌或结肠癌。
- 一种用于治疗或预防肿瘤的方法,所述方法包括给予有需要的受试者治疗有效量的根据权利要求1-7中任一项所述的重组病毒载体、根据权利要求8所述的免疫组合物或根据权利要求9所述的肿瘤疫苗;优选地,所述肿瘤为恶性肿瘤;更优选地,所述恶性肿瘤为乳腺癌或结肠癌。。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2019/116197 WO2021087851A1 (zh) | 2019-11-07 | 2019-11-07 | 一种重组病毒载体、包含其的免疫组合物以及用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2019/116197 WO2021087851A1 (zh) | 2019-11-07 | 2019-11-07 | 一种重组病毒载体、包含其的免疫组合物以及用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021087851A1 true WO2021087851A1 (zh) | 2021-05-14 |
Family
ID=75849492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2019/116197 WO2021087851A1 (zh) | 2019-11-07 | 2019-11-07 | 一种重组病毒载体、包含其的免疫组合物以及用途 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2021087851A1 (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103626877A (zh) * | 2013-11-27 | 2014-03-12 | 苏州工业园区唯可达生物科技有限公司 | 含ny-eso-1的融合蛋白、制备方法及应用 |
WO2018005559A1 (en) * | 2016-06-27 | 2018-01-04 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
US20180000912A1 (en) * | 2016-03-04 | 2018-01-04 | New York University | Virus Vectors Expressing Multiple Epitopes of Tumor Associated Antigens For Inducing Antitumor Immunity |
CN109575141A (zh) * | 2017-09-29 | 2019-04-05 | 苏州工业园区唯可达生物科技有限公司 | 一种cd4辅助性t细胞表位融合肽及其疫苗 |
CN110205340A (zh) * | 2017-09-29 | 2019-09-06 | 苏州工业园区唯可达生物科技有限公司 | 一种重组病毒载体、包含其的免疫组合物以及用途 |
-
2019
- 2019-11-07 WO PCT/CN2019/116197 patent/WO2021087851A1/zh active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103626877A (zh) * | 2013-11-27 | 2014-03-12 | 苏州工业园区唯可达生物科技有限公司 | 含ny-eso-1的融合蛋白、制备方法及应用 |
US20180000912A1 (en) * | 2016-03-04 | 2018-01-04 | New York University | Virus Vectors Expressing Multiple Epitopes of Tumor Associated Antigens For Inducing Antitumor Immunity |
WO2018005559A1 (en) * | 2016-06-27 | 2018-01-04 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
CN109575141A (zh) * | 2017-09-29 | 2019-04-05 | 苏州工业园区唯可达生物科技有限公司 | 一种cd4辅助性t细胞表位融合肽及其疫苗 |
CN110205340A (zh) * | 2017-09-29 | 2019-09-06 | 苏州工业园区唯可达生物科技有限公司 | 一种重组病毒载体、包含其的免疫组合物以及用途 |
Non-Patent Citations (3)
Title |
---|
BOLLI MARTIN, SCHULTZ-THATER ELKE, ZAJAC PAUL, GULLER ULRICH, FEDER CHANTAL, SANGUEDOLCE FRANCESCA, CARAFA VINCENZA, TERRACCIANO L: "NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: A tissue microarray study", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC., US, vol. 115, no. 6, 20 July 2005 (2005-07-20), US, pages 960 - 966, XP055809532, ISSN: 0020-7136, DOI: 10.1002/ijc.20953 * |
DYRSKJØT L, ZIEGER K, KISSOW LILDAL T, REINERT T, GRUSELLE O, COCHE T, BORRE M, ØRNTOFT T F: "Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, GB, vol. 107, no. 1, 1 June 2012 (2012-06-01), GB, pages 116 - 122, XP055809533, ISSN: 0007-0920, DOI: 10.1038/bjc.2012.215 * |
XING BAOCAI, YUAN YAN-HUA, HU ZHI-GUO, LIU YUE-XIANG, HAN YAN, LIU NIAN, CHEN WEI-FENG, WANG YU: "Expression of NY-ESO-1/LAGE-1 genes in hepatocellular carcinoma and autologous humoral responses induced thereby", NATIONAL MEDICAL JOURNAL OF CHINA, vol. 84, no. 23, 1 December 2004 (2004-12-01), pages 1980 - 1982, XP055809529 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6945301B2 (ja) | Hpvおよび関連する疾病のための免疫増強治療ワクチン | |
Chen et al. | Experimental vaccine strategies for cancer immunotherapy | |
KR102684237B1 (ko) | 개인 맞춤형 백신 | |
EP4052724A1 (en) | Formulations for neoplasia vaccines | |
JP5709264B2 (ja) | ワクチン組成物および方法 | |
WO2019062234A1 (zh) | 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 | |
US20100303868A1 (en) | Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases | |
WO2020024982A1 (zh) | 一种基于减毒李斯特菌激活的抗原提呈细胞的肿瘤免疫治疗组合物、制备方法和应用 | |
WO2020062930A1 (zh) | 一种重组病毒载体、包含其的免疫组合物以及用途 | |
KR101810840B1 (ko) | 암의 예방 및 치료용 msi-특이적 프레임쉬프트 펩티드(fsp) | |
EP2572725B1 (en) | MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer | |
Vangasseri et al. | Lipid-protamine-DNA-mediated antigen delivery | |
Yang et al. | Co-transfection of dendritic cells with AFP and IL-2 genes enhances the induction of tumor antigen-specific antitumor immunity | |
WO2021087851A1 (zh) | 一种重组病毒载体、包含其的免疫组合物以及用途 | |
Bronte | Genetic vaccination for the active immunotherapy of cancer | |
WO2021163874A1 (zh) | 一种重组病毒载体、包含其的免疫组合物以及用途 | |
KR19990063672A (ko) | 표적배향된 미립자물 유전 면역화에 의한 세포-매개 면역응답의 자극. | |
CN110923266A (zh) | 一种重组病毒载体、包含其的免疫组合物以及用途 | |
Velek | Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects | |
WO2013083287A1 (en) | Hpv derived polynucleic acids for therapy | |
JP2003522195A (ja) | 肝細胞癌の治療のための方法及び組成物 | |
JP7543419B2 (ja) | 組換えウイルスベクター、それを含む免疫組成物及び用途 | |
KR20110117654A (ko) | 면역 자극에 있어서의 사카로미세스 세레비지아에 미토콘드리아 핵산 분획물의 용도 | |
CA2799803C (en) | Msi-specific frameshift peptides (fsp) for prevention and treatment of cancer | |
Harrigan | The promise of vaccines and gene therapy in skin disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19951760 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19951760 Country of ref document: EP Kind code of ref document: A1 |